Local‐regional recurrence risk after autologous fat grafting in breast cancer patients: A systematic review and meta‐analysis

IntroductionAromatase inhibitor-induced arthralgia (AIA) is a major adverse event of aromatase inhibitors (AIs) and leads to premature discontinuation of AI therapy in breast cancer patients. The objective of this protocol for a systematic review and network meta-analysis (NMA) is to provide the methodology to compare the change in pain intensity between different AIA treatments and demonstrate the rank probabilities for different treatments by combining all available direct and indirect evidence.Methods and analysisPubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE, Web of Science and ClinicalTrials.gov will be searched to identify publications in English from inception to November 2019. We will include randomised controlled trials (RCTs) assessing the effects of different treatments for AIA in postmenopausal women with stage 0–III hormone receptor-positive breast cancer. The primary endpoints will be the change in patient-reported pain intensity from baseline to post-treatment. The number of adverse events will be presented as a secondary outcome.Both pairwise meta-analysis and NMA with the Frequentist approach will be conducted. We will demonstrate summary estimates with forest plots in meta-analysis and direct and mixed evidence with a ranking of the treatments as the P-score in NMA. The revised Cochrane risk-of-bias tool for randomised trials will be used to assess the methodological quality within individual RCTs. The quality of evidence will be assessed.Ethics and disseminationAs this review does not involve individual patients, ethical approval is not required. The results of this systematic review and NMA will be published in a peer-reviewed journal. This review will provide valuable information on AIA therapeutic options for clinicians, health practitioners and breast cancer survivors.PROSPERO registration numberCRD42019136967.

Download Full-text

54P Overweight and prognosis in triple-negative breast cancer patients: A systematic review and meta-analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.03.068 ◽

2021 ◽

Vol 32 ◽

pp. S43-S44

Author(s):

K.S. Harborg ◽

R. Zachariae ◽

J. Olsen ◽

M. Johannsen ◽

D. Cronin-Fenton ◽

...

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Cancer Patients ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Meta Analysis ◽

Breast Cancer Patients

Download Full-text

Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis

Oncotarget ◽

10.18632/oncotarget.7219 ◽

2016 ◽

Vol 7 (9) ◽

pp. 10373-10385 ◽

Cited By ~ 25

Author(s):

Weige Tan ◽

Qian Li ◽

Kai Chen ◽

Fengxi Su ◽

Erwei Song ◽

...

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Estrogen Receptor ◽

Prognostic Factor ◽

Cancer Patients ◽

Meta Analysis ◽

Estrogen Receptor Beta ◽

Breast Cancer Patients ◽

Receptor Beta

Download Full-text

Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis

10.21873/anticanres.11960 ◽

2017 ◽

Vol 37 (10) ◽

Cited By ~ 2

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Cancer Patients ◽

Meta Analysis ◽

Acute Radiation ◽

Radiation Dermatitis ◽

Breast Cancer Patients ◽

Topical Management

Download Full-text

High Moesin Expression Is a Predictor of Poor Prognosis of Breast Cancer: Evidence From a Systematic Review With Meta-Analysis

Frontiers in Oncology ◽

10.3389/fonc.2021.650488 ◽

2021 ◽

Vol 11 ◽

Author(s):

Xiaoli Hu ◽

Yang Liu ◽

Zhitong Bing ◽

Qian Ye ◽

Chengcheng Li

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Systematic Review ◽

Cancer Patients ◽

Poor Prognosis ◽

Data Extraction ◽

Meta Analysis ◽

Gene Expression Omnibus ◽

Breast Cancer Patients ◽

Node Metastases

Owing to metastases and drug resistance, the prognosis of breast cancer is still dismal. Therefore, it is necessary to find new prognostic markers to improve the efficacy of breast cancer treatment. Literature shows a controversy between moesin (MSN) expression and prognosis in breast cancer. Here, we aimed to conduct a systematic review and meta-analysis to evaluate the prognostic relationship between MSN and breast cancer. Literature retrieval was conducted in the following databases: PubMed, Web of Science, Embase, and Cochrane. Two reviewers independently performed the screening of studies and data extraction. The Gene Expression Omnibus (GEO) database including both breast cancer gene expression and follow-up datasets was selected to verify literature results. The R software was employed for the meta-analysis. A total of 9 articles with 3,039 patients and 16 datasets with 2,916 patients were ultimately included. Results indicated that there was a significant relationship between MSN and lymph node metastases (P < 0.05), and high MSN expression was associated with poor outcome of breast cancer patients (HR = 1.99; 95% CI 1.73–2.24). In summary, there is available evidence to support that high MSN expression has valuable importance for the poor prognosis in breast cancer patients.Systematic Review Registrationhttps://inplasy.com/inplasy-2020-8-0039/.

Download Full-text